No Association Between Serum Adenosine Deaminase Activity and Disease Activity in Crohn’s Disease
- 149 Downloads
Adenosine deaminase activity is proposed as a marker of inflammation in some inflammatory conditions.
To investigate the association of serum adenosine deaminase activity and disease activity in Crohn’s disease patients.
In a cross-sectional study, 30 consecutive known cases of Crohn’s disease (15 with active disease and 15 in remission) referring to a university hospital in Tehran (Iran) and 15 age- and gender-matched healthy controls were studied. Disease activity was assessed using the Crohn’s disease activity index (cutoff >150). Total serum adenosine deaminase activity, C-reactive protein, erythrocyte sedimentation rate, and fecal calprotectin were evaluated in patients. Serum adenosine deaminase activity was measured in controls.
Mean age of the patients was 36.8 ± 12.6 years, and 56.7 % were male. Serum adenosine deaminase activity in patients with active disease, patients in remission, and controls was 12.3 ± 5.9, 14.6 ± 6.2, and 11.9 ± 6.4 U/L, respectively (P = 0.458). Compared with patients in remission, those with active disease had higher erythrocyte sedimentation rate (40.4 ± 30.6 vs. 16.9 ± 16.0 mm/h, P = 0.014) and higher frequency of positive C-reactive protein (66.6 vs. 13.3 %, P = 0.004) and positive fecal calprotectin tests (86.6 vs. 33.3 %, P = 0.004). Serum adenosine deaminase activity was not correlated with erythrocyte sedimentation rate (r = 0.05, P = 0.761) and was not different between patients with positive and negative C-reactive protein (12.2 ± 5.4 vs. 14.2 ± 6.5 U/L, P = 0.393) and fecal calprotectin tests (11.7 ± 5.3 vs. 16.0 ± 6.5 U/L, P = 0.063).
In patients with Crohn’s disease, serum adenosine deaminase activity is not associated with clinical disease activity or with other inflammation markers and cannot be suggested as an inflammation marker.
KeywordsInflammatory bowel diseases Crohn’s disease Adenosine deaminase Fecal calprotectin Biological markers
This study is supported by the Tehran University of Medical Sciences. The sponsor had no role in the study design, the collection, analysis and interpretation of data, writing of the manuscript, or the decision to submit the manuscript for publication. Authors contributions were as follows: MS and NED participated in study design, data collection, and editing the manuscript. AGh did data analysis and prepared the manuscript draft. All authors studied, revised, and approved the final version of manuscript.
Conflict of interest
- 28.Giusti G, Galanti B. Colorimetric method. In: Bergmeyer HU, ed. Methods of enzymatic analysis. Weinheim: Verlag Chemie; 1984:315–323.Google Scholar
- 29.Daperno M, Castiglione F, de Ridder L, et al. Results of the 2nd part Scientific Workshop of the ECCO. II: measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis. 2011;5:484–498.Google Scholar
- 34.Waugh N, Cummins E, Royle P, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess. 2013;17:xv–xix, 1–211.Google Scholar